Financial Summary (All financials)
| In millions of JPY, except per share items | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 |
| Revenues | 8,108 | 1,565 | 700,130 | 694,393 | 1,496,969 | 1,403,197 | 1,395,681 | 1,930,588 |
| Revenue growth | 418.1% | -99.8% | 0.8% | -53.6% | 6.7% | 0.5% | -27.7% | 5.4% |
| Cost of goods sold | 599,248 | 580,273 | 552,406 | 562,005 | 598,536 | 566,221 | 652,602 | 76,112 |
| Gross profit | -591,140 | -578,708 | 147,724 | 132,388 | 898,433 | 836,976 | 743,079 | 1,854,476 |
| Gross margin | -7290.8% | -36978.1% | 21.1% | 19.1% | 60.0% | 59.6% | 53.2% | 96.1% |
| Selling, general and administrative | 15,641 | 13,520 | 31,885 | 36,915 | 36,762 | 35,111 | 35,892 | 35,230 |
| Research and development | 184,319 | 178,835 | 170,317 | 166,865 | 184,781 | 175,280 | 189,910 | 192,300 |
| EBITA | 546,932 | 490,650 | 935,810 | 691,362 | 803,904 | 634,404 | 532,206 | 1,040,834 |
| EBITA margin | 6745.6% | 31351.4% | 133.7% | 99.6% | 53.7% | 45.2% | 38.1% | 53.9% |
| Amortization of intangibles | 1,717 | 2,296 | 1,662 | 2,504 | 3,324 | 4,535 | 5,181 | 4,979 |
| EBIT | 545,215 | 488,354 | 934,148 | 688,858 | 800,580 | 629,869 | 527,025 | 1,035,855 |
| EBIT margin | 6724.4% | 31204.7% | 133.4% | 99.2% | 53.5% | 44.9% | 37.8% | 53.7% |
| Pre-tax income | 221,000 | 219,126 | 269,588 | -30,497 | 326,260 | 316,179 | 185,849 | 322,074 |
| Income taxes | 80,090 | 70,274 | 28,894 | 57,010 | 103,866 | 80,229 | 22,596 | 120,780 |
| Tax rate | 36.2% | 32.1% | 10.7% | | 31.8% | 25.4% | 12.2% | 37.5% |
| Net income | 142,996 | 153,116 | 216,998 | -100,442 | 219,343 | 239,617 | 131,550 | 224,785 |
| Net margin | 1763.6% | 9783.8% | 31.0% | -14.5% | 14.7% | 17.1% | 9.4% | 11.6% |
| |
| Diluted EPS | $45.27 | $48.65 | $66.23 | ($29.90) | $0.00 | $65.69 | $35.55 | $60.04 |
| Shares outstanding (diluted) | 3,159 | 3,147 | 3,277 | 3,360 | 3,543,602,532 | 3,648 | 3,700 | 3,744 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|